Weekly Analyst Rating Changes for 4D Molecular Therapeutics (FDMT)

A number of firms have changed their ratings and price targets on the stock 4D molecular therapeutics (NASDAQ: FDMT) recently:

• 09/19/2024 – 4D Molecular Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $36.00 target price on the stock, down previously from $40.00.
• 09/19/2024 – 4D Molecular Therapeutics had its price target raised by analysts at Chardan Capital from $38.00 to $39.00. They now have a “buy” rating on the stock.
• 09/19/2024 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 target price on the stock.
• 09/09/2024 – 4D Molecular Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 08/09/2024 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 target price on the stock.
• 07/22/2024 – 4D Molecular Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $40.00 target price on the stock.

4D Molecular Therapeutics trading down 11.9%

FDMT traded down $1.60 during mid-day trading on Friday, reaching $11.90. 2,125,071 shares of the stock were exchanged, compared to its average volume of 890,993. The company’s fifty day moving average is $16.12 and its two hundred day moving average is $22.59. 4D Molecular Therapeutics, Inc. has a 1 year low of $9.44 and a 1 year high of $36.25. The company has a market cap of $615.27 million, a PE ratio of -4.88 and a beta of 2.80.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $1.90 million. As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will show -2.75 earnings per share for the current year.

Insider Trading at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, CEO David Kirn sold 12,930 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other 4D Molecular Therapeutics news, CEO David Kirn sold 12,930 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The sale was disclosed in a legal filing with the SEC, which is available on the SEC’s website. Also, insider Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.36, for a total transaction of $90,737.28. Following the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $37,102.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,347 shares of company stock worth $785,566. 7.30% of shares are currently owned by company insiders.

Hedge funds weigh in on 4D molecular therapy

Several large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its position in shares of 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after purchasing an additional 3,026 shares in the last quarter. Quest Partners LLC grew its position in 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after buying an additional 5,745 shares in the last quarter . Entropy Technologies LP purchased a new position in 4D Molecular Therapeutics in the first quarter valued at $239,000. China Universal Asset Management Co. Ltd. raised its stake in 4D Molecular Therapeutics by 93.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,579 shares of the company’s stock valued at $305,000 after purchasing an additional 4,628 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $344,000. Institutional investors and hedge funds own 99.27% ​​of the company’s shares.

4D Molecular Therapeutics, Inc, a clinical-stage biotherapy company, develops gene medicines using its therapeutic vector evolution platform in the Netherlands and the United States. The company is developing a portfolio of gene medicine product candidates focused on three therapeutic areas of ophthalmology, cardiology and pulmonology.

Read more

Get daily news and ratings for 4D Molecular Therapeutics Inc – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for 4D Molecular Therapeutics Inc and related companies with MarketBeat.com ‘s FREE daily email newsletter.